First Patient Enrolled in Phase 2 Study of Zuclomiphene Citrate for Treatment of Hot Flashes Caused by Androgen Deprivation Therapy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. TTAN
2. CHYM
3. BRZE
4. USO
5. QCOM
6. DYN
7. PHVS
8. GENI
9. INGM
10. ASO

Go back to First Patient Enrolled in Phase 2 Study of Zuclomiphene Citrate for Treatment of Hot Flashes Caused by Androgen Deprivation Therapy
(NASDAQ: VERU) Delayed: 2.58 --0 (-0%)
Previous Close $2.58    52 Week High $ 
Open $2.58    52 Week Low $ 
Day High $2.58    P/E N/A 
Day Low $2.58    EPS $ 
Volume 7,376